Why the study?
Does encainide reduce ventricular arrhythmia and affect left ventricular function in patients with chronic, high-grade ventricular arrhythmia?
Population
21 patients with chronic, high-grade ventricular arrhythmia
Comparison
Encainide (intravenous and oral) for 3 months vs Placebo
Design
Single-blind
Follow-up
3 months
Authors
Loading...
Encainide suppresses VPCs without LV impairment; leaves open net benefit given proarrhythmia risk in Level 5 data.
Does encainide reduce ventricular arrhythmia and affect left ventricular function in patients with chronic, high-grade ventricular arrhythmia?
While encainide effectively reduces the frequency of ventricular premature complexes without impairing left ventricular performance, it carries a significant risk of proarrhythmia, including new sustained ventricular tachycardia.
DiBianco et al. (1982) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: